Nu-Med Financial Statements From 2010 to 2026
| NUMD Stock | USD 0.02 0 22.54% |
Check Nu-Med Plus financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nu-Med Plus' main balance sheet or income statement drivers, such as , as well as many indicators such as . Nu-Med financial statements analysis is a perfect complement when working with Nu-Med Plus Valuation or Volatility modules.
Nu-Med |
Nu Med Plus OTC Stock Return On Equity Analysis
Nu-Med Plus' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nu-Med Plus Return On Equity | -545.23 |
Most of Nu-Med Plus' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nu Med Plus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nu Med Plus has a Return On Equity of -545.2325. This is much higher than that of the Healthcare sector and notably higher than that of the Medical Devices industry. The return on equity for all United States stocks is notably higher than that of the company.
Nu Med Plus Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nu-Med Plus's current stock value. Our valuation model uses many indicators to compare Nu-Med Plus value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nu-Med Plus competition to find correlations between indicators driving Nu-Med Plus's intrinsic value. More Info.Nu Med Plus is regarded third in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Nu-Med Plus' earnings, one of the primary drivers of an investment's value.About Nu-Med Plus Financial Statements
Nu-Med Plus stakeholders use historical fundamental indicators, such as Nu-Med Plus' revenue or net income, to determine how well the company is positioned to perform in the future. Although Nu-Med Plus investors may analyze each financial statement separately, they are all interrelated. For example, changes in Nu-Med Plus' assets and liabilities are reflected in the revenues and expenses on Nu-Med Plus' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Nu Med Plus. Please read more on our technical analysis and fundamental analysis pages.
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah. Nu Med operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 2 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Nu-Med OTC Stock
Nu-Med Plus financial ratios help investors to determine whether Nu-Med OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nu-Med with respect to the benefits of owning Nu-Med Plus security.